Skip to content
1st Counsel – Lifestyle
Author:
Brii Biosciences Limited
Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B
July 2, 2026
Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV
May 27, 2026
Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026
April 26, 2026
DPC Dash Ltd Announces Full Year 2025 Financial Results
March 25, 2026
Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results
March 19, 2026